Skip to Content
Biotechnology and health

A massive genome-sequencing effort is coming to India

March 19, 2018

Singapore-based genomics company Global Gene Corp is partnering with biotech giant Regeneron to build the largest collection of DNA sequenced from people in India.

Why India? The lack of diversity in genomic data is a problem. Most of the worldwide genomic data available to researchers is from people of European heritage. India is home to 1.3 billion people and represents 20 percent of the world’s population, yet less than 1 percent of the world’s genomic data comes from the subcontinent.

The goal: Global Gene Corp didn’t say exactly how many genomes it hopes to sequence over the next few years but said the project will be on the scale of Genomics England, which aims to sequence 100,000 people’s genomes in the UK. The DNA sequences generated from the Indian effort will be paired with people’s medical records to look for genetic links to disease.

Why it matters: Studying Indian genomes could uncover unique genetic risk factors for diseases and explain why some ailments occur more or less often in Indian populations than in Westerners. It could also help identify new or better drugs. “Our view is to drive the same change in health care through genomics that the mobile revolution brought to India,” says Global Gene Corp CEO Sumit Jamuar.

Deep Dive

Biotechnology and health

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

The quest to legitimize longevity medicine

Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.

There is a new most expensive drug in the world. Price tag: $4.25 million

But will the latest gene therapy suffer the curse of the costliest drug?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.